311
Views
0
CrossRef citations to date
0
Altmetric
Epidemiology

Epidemiological and clinical profile of amyotrophic lateral sclerosis in Ethiopia: a 5-year multicenter retrospective study

ORCID Icon, , , , , , , , , , , , , , , , , , , , & ORCID Icon show all
Pages 678-686 | Received 09 May 2023, Accepted 30 Jun 2023, Published online: 26 Jul 2023

References

  • Martin S, Al Khleifat A, Al-Chalabi A. What causes amyotrophic lateral sclerosis? F1000Res. 2017;6:371.
  • Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.
  • Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. In: Handbook of clinical neurology. Elsevier; 2016;138:225–38 [cited June 21, 2023]. Available at: https://linkinghub.elsevier.com/retrieve/pii/B9780128029732000136
  • Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AHM, Butt D, et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol. 2006;253:1642–3.
  • Ryan M, Heverin M, McLaughlin RL, Hardiman O. Lifetime risk and heritability of amyotrophic lateral sclerosis. JAMA Neurol. 2019;76:1367–74.
  • Rosenbohm A, Fan D, Manganelli F, Podnar S, Falcão De Campos C. Trends in the diagnostic delay and pathway for amyotrophic lateral sclerosis patients across different countries. Front Neurol. 2023;13. doi:10.3389/fneur.2022.1064619.
  • Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310–23.
  • Gowland A, Opie-Martin S, Scott KM, Jones AR, Mehta PR, Batts CJ, et al. Predicting the future of ALS: the impact of demographic change and potential new treatments on the prevalence of ALS in the United Kingdom, 2020–2116. Amyotroph Lateral Scler Front Degener. 2019;20:3–4.
  • Arthur KC, Calvo A, Price TR, Geiger JT, Chiò A, Traynor BJ. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. 2016;7:12408.
  • Braga AC, Gromicho M, Pinto S, de Carvalho M, Henning F. A comparative study of South African and Portuguese amyotrophic lateral sclerosis cohorts. J Neurol Sci. 2020;414:116857.
  • Tiruneh BT, McLelland G, Plummer V. National healthcare system development of Ethiopia: a systematic narrative review. Hosp Top. 2020;98:37–44.
  • Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169:13–21.
  • Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci. 1994;124 Suppl:96–107.
  • Fang T, Al Khleifat A, Stahl DR, Lazo La Torre C, Murphy C, Young C, et al. Comparison of the King’s and MiToS staging systems for ALS. Amyotroph Lateral Scler Front Degener. 2017;18:3–4.
  • Lo Coco D, Marchese S, La Bella V, Piccoli T, Lo Coco A. The amyotrophic lateral sclerosis functional rating scale predicts survival time in amyotrophic lateral sclerosis patients on invasive mechanical ventilation. Chest. 2007;132:64–9.
  • Project MinE ALS Sequencing Consortium. Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. Eur J Hum Genet. 2018;26:1537–1546.
  • Al Khleifat A, Iacoangeli A, van Vugt JJFA, Bowles H, Moisse M, Zwamborn RAJ, et al. Structural variation analysis of 6500 whole genome sequences in amyotrophic lateral sclerosis. NPJ Genom Med. 2022;7:8.
  • Kacem I, Sghaier I, Bougatef S, Nasri A, Gargouri A, Ajroud-Driss S, et al. Epidemiological and clinical features of amyotrophic lateral sclerosis in a Tunisian cohort. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:131–9.
  • Rashed HR, Tork MA. Diagnostic dilemma of amyotrophic lateral sclerosis (ALS): insights from the first ALS specialized clinic in Egypt. Egypt J Neurol Psychiatry Neurosurg. 2020;56. doi:10.1186/s41983-020-00203-1
  • Gams MD, Touré K, Sow AD, Nyassinde J, Mapoure N4, Ndiaye M, et al. Environmental and occupational risk factors of amyotrophic lateral sclerosis in Senegal. Afr J Neurol Sci. 2018;37:32–7.
  • Drory VE, Artmonov I. Earlier onset and shorter survival of amyotrophic lateral sclerosis in Jewish patients of North African origin. J Neurol Sci. 2007;258:39–43.
  • Rashed HR, Tork MA. Diagnostic delay among ALS patients: Egyptian study. Amyotroph Lateral Scler Front Degener. 2020;21:5–6.
  • Chiò A, Mora G, Calvo A, Mazzini L, Bottacchi E, Mutani R, PARALS. Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology. 2009;72:725–31.
  • Wolf J, Safer A, Wöhrle JC, Palm F, Nix WA, Maschke M, et al. Factors predicting one-year mortality in amyotrophic lateral sclerosis patients – data from a population-based registry. BMC Neurol. 2014;14:197.
  • Byrne S, Jordan I, Elamin M, Hardiman O. Age at onset of amyotrophic lateral sclerosis is proportional to life expectancy. Amyotroph Lateral Scler Front Degener. 2013;14:7–8.
  • Conte A, Lattante S, Luigetti M, Del Grande A, Romano A, Marcaccio A, et al. Classification of familial amyotrophic lateral sclerosis by family history: effects on frequency of genes mutation. J Neurol Neurosurg Psychiatry. 2012;83:1201–3.
  • Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. Arch Neurol. 2000;57:1171–6.
  • Byrne S, Walsh C, Lynch C, Bede P, Elamin M, Kenna K, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82:623–7.
  • Byrne S, Bede P, Elamin M, Kenna K, Lynch C, McLaughlin R, et al. Proposed criteria for familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12:157–9.
  • Beghi E, Millul A, Micheli A, Vitelli E, Logroscino G, SLALOM Group. Incidence of ALS in Lombardy, Italy. Neurology. 2007;68:141–5.
  • Chiò A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology. 2002;59:99–103.
  • Carrat P, Spicuzza L, Cassano A, Maniscalco M, Gadaleta F, Lacedonia D, et al. Early treatment with noninvasive positive pressure ventilation prolongs survival in amyotrophic lateral sclerosis patients with nocturnal respiratory insufficiency. Orphanet J Rare Dis. 2009;4:10.
  • Leonardis L, Dolenc Grošelj L, Vidmar G. Factors related to respiration influencing survival and respiratory function in patients with amyotrophic lateral sclerosis: a retrospective study. Eur J Neurol. 2012;19:1518–24.
  • Beghi E, Millul A, Logroscino G, Vitelli E, Micheli A, SLALOM GROUP. Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008;9:163–7.
  • Lee CTC, Chiu YW, Wang KC, Hwang CS, Lin KH, Lee IT, et al. Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 cases in Taiwan. J Epidemiol. 2013;23:35–40.
  • Chiò A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41:118–30. Vol

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.